U.S. judge rejects Amgen bid to block 'biosimilar' Neupogen

NEW YORK (Reuters) - A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen's blockbuster drug used to prevent infections in cancer patients.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news